Tag Archives: Gallium-68 Octreotide PET scan

RadioMedix $2.8 Million Grant from Texas Emerging Technology Fund to Result in New Products that Benefit Carcinoid and Neuroendocrine Cancer Patients

Two innovative products that will enable users to generate and label PET radiotracers on-site at a significantly reduced cost will be developed by RadioMedix, Inc. with a $2.8 million grant from the Texas Emerging Technology Fund.  According to Ebrahim S. … Continue reading

Posted in carcinoid, carcinoid and neuroendocrine tumor treatments, carcinoid specialists, clinical trials, NET (neuroendocrine tumor) cancer, neuroendocrine cancer, neuroendocrine tumors, nuclear imaging | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Leave a comment